Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.

Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.

Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.

SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.

The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.

Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.